All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Silverback Therapeutics Inc. lifted the shades on its secretive operation just enough to reveal an extension of its series A round, previously cited only in SEC filings, to $47.5 million. The financing was led by existing investor Orbimed with participation from new investors Celgene Corp. and Alexandria Venture Investments.